of all of Cleveland Avenue’s various investment funds, including Presto CA, LLC. CA is a lender under the CA Note and is party to (i) that certain Amended and Restated Governance Agreement, dated as of November 16, 2023 (the “Governance Agreement”), pursuant to which, among other things, CA has the right to appoint one of our directors and (ii) that certain Stockholders Agreement, dated as of November 16, 2023 (the “Stockholders Agreement”), pursuant to which we agreed that we will not undertake certain actions for a period of 12 months without the consent of the parties thereto.
On March 1, 2024 the Company issued the March 2024 Convertible Note in the principal amount of $960,000 in consideration for a cash investment of $960,000 from Remus Capital, a related party affiliated with Krishna Gupta, a director of the Company. Remus is party to (i) the Governance Agreement, pursuant to which, among other things, Remus Capital has the right to appoint two directors of the Company and (ii) the Stockholders Agreement, pursuant to which the Company agreed that it will not undertake certain actions for a period of 12 months without the consent of the parties thereto.
On January 29, 2024, in connection with the January 2024 Offering, we entered into a securities purchase agreement with Remus Capital for the issuance and sale of $2.7 million of the January 2024 Convertible Notes. From issuance through September 30, 2024, the Conversion Price will be reduced if the Company issues any common stock or securities convertible into or exchangeable for common stock at a price that is less than the initial conversion price of $0.25 per share.
In addition, we are party to a Stockholders Agreement, dated as of November 16, 2023, by and among us, Presto CA, LLC (“CA”) and KKG Enterprises LLC (“KKG”), each a related party, pursuant to which, CA and KKG have consent rights with respect to, among other things, any issuance of common stock or securities convertible into or exercisable for common stock, subject to limited exceptions. Each of CA and KKG may have the ability to block any such future issuances pursued and the we may therefore not be able to raise capital as needed.
On November 21, 2023, we entered into the November Purchase Agreements, one of which was with Zaffran Special Opportunities, LLC, a related party, to which we agreed to issue 750,000 newly issued shares of our common stock.
On October 10, 2023, we entered into the October Purchase Agreement with Presto CA, LLC, pursuant to which we agreed to sell 1,500,000 newly issued shares of our common stock, at a purchase price of $2.00 per share for an aggregate purchase price of $3.0 million.
As a result of anti-dilution provisions in the October Purchase Agreement, we issued 1,500,000 additional shares to the purchaser CA upon the issuance of common stock in the November 2023 Offering and the triggering purchase price was lowered from $2.00 to $1.00 per share. We recorded deemed dividend and an offsetting entry to additional paid-in capital of $1.5 million as a result. The anti-dilution provisions were further triggered upon the issuance of the January 2024 Convertible Notes where an additional 4,500,000 shares were issued to CA and the triggering purchase price was lowered from $1.00 to $0.40 per share. We recorded a deemed dividend with an offsetting entry to additional paid-in capital of $2.7 million as a result. The anti-dilution provisions were further triggered upon the issuance of common stock in the February Offering where an additional 4,500,000 shares were issued to CA and the triggering purchase price was lowered from $0.40 to $0.25 per share. We recorded a deemed dividend and an offsetting entry to additional paid-in capital of $0.7 million as a result.
During the nine months ended March 31, 2023, we received an equity investment of $1.0 million from an investor in exchange for 133,333 shares of our common stock. Such investor held a significant portion of outstanding convertible notes on September 15, 2022, the date the investment was made. Refer to Note 9 of our condensed consolidated financial statements included within Item 1 of this Quarterly Report on Form 10-Q for further details.
In addition, during the nine months ended March 31, 2023 we granted 1,200,000 of RSUs to a director and former interim CEO of ours with a grant date fair value of $4.56 per RSU. Refer to Note 11 of our condensed consolidated financial statements included within Item 1 of this Quarterly Report on Form 10-Q for further details.
Critical Accounting Policies and Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of certain assets, liabilities, revenues, expenses and disclosures. Accordingly, actual amounts could differ from those estimates, and those differences could be material.